CO2017001387A2 - Proceso para purificación de rhu-gcsf - Google Patents

Proceso para purificación de rhu-gcsf

Info

Publication number
CO2017001387A2
CO2017001387A2 CONC2017/0001387A CO2017001387A CO2017001387A2 CO 2017001387 A2 CO2017001387 A2 CO 2017001387A2 CO 2017001387 A CO2017001387 A CO 2017001387A CO 2017001387 A2 CO2017001387 A2 CO 2017001387A2
Authority
CO
Colombia
Prior art keywords
purification
rhu
gcsf
csf
recovery
Prior art date
Application number
CONC2017/0001387A
Other languages
English (en)
Inventor
Arjun Raghuwanshi
Shrawan Kumar Singh
Nidhiben Thaker
Shagun Shankar
Pavan Kardile
Sanjay Singh
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of CO2017001387A2 publication Critical patent/CO2017001387A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invención proporciona un proceso de recuperación y purificación o corriente abajo para la purificación de G-CSF humana recombinante.
CONC2017/0001387A 2014-07-14 2017-02-13 Proceso para purificación de rhu-gcsf CO2017001387A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2289MU2014 2014-07-14
PCT/IN2015/050066 WO2016009451A2 (en) 2014-07-14 2015-07-13 A novel process for purification of rhu-gcsf

Publications (1)

Publication Number Publication Date
CO2017001387A2 true CO2017001387A2 (es) 2017-05-10

Family

ID=55079140

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0001387A CO2017001387A2 (es) 2014-07-14 2017-02-13 Proceso para purificación de rhu-gcsf

Country Status (13)

Country Link
US (1) US10519209B2 (es)
EP (1) EP3169697A4 (es)
JP (1) JP6742300B2 (es)
AU (1) AU2015291123C1 (es)
BR (1) BR112017000704A2 (es)
CL (1) CL2017000087A1 (es)
CO (1) CO2017001387A2 (es)
EA (1) EA035448B1 (es)
MX (1) MX2017000467A (es)
NZ (1) NZ728662A (es)
PE (2) PE20220371A1 (es)
SA (1) SA517380723B1 (es)
WO (1) WO2016009451A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102020995B1 (ko) * 2017-10-30 2019-09-16 한국코러스 주식회사 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법
CN109840410B (zh) * 2017-12-28 2021-09-21 中国科学院计算技术研究所 一种进程内数据隔离与保护的方法和系统
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
US20220195002A1 (en) * 2019-04-24 2022-06-23 Tanvex Biopharma Usa, Inc. Process for preparing granulocyte-colony stimulating factor
WO2022167886A1 (en) * 2021-02-04 2022-08-11 Intas Pharmaceuticals Ltd. An improved peg-gcsf purification process having dual ufdf
WO2022245259A1 (ru) * 2021-05-18 2022-11-24 Акционерное общество "ГЕНЕРИУМ" Способ промышленной очистки ромиплостима

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ218336A (en) 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
DE69838552T2 (de) * 1997-07-14 2008-05-21 Bolder Biotechnology, Inc., Louisville Derivate des wachstumshormons und verwandte proteine
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
FR2796071B1 (fr) 1999-07-08 2001-09-07 Hoechst Marion Roussel Inc Procede de purification de facteur de stimulation de colonies de granulocytes
CN1663962A (zh) 2004-03-01 2005-09-07 重庆富进生物医药有限公司 重组人粒细胞集落刺激因子及其化学修饰物的一步纯化工艺
JP2007277094A (ja) * 2004-06-29 2007-10-25 Chemo Sero Therapeut Res Inst 改変ダニ主要アレルゲン含有医薬組成物
DE102005033250A1 (de) * 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
EP2044118A2 (en) * 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
WO2008096370A2 (en) * 2007-02-05 2008-08-14 Natco Pharma Limited An efficient and novel purification method of recombinant hg-csf
US7625555B2 (en) * 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
RS53010B (en) * 2009-12-31 2014-04-30 Arven Ilac Sanayi Ve Ticaret A.S. NEW PROCEDURE FOR PREPARATION OF G-CSF (GRANULOCITE COLONY STIMULATION FACTOR)
CN102234310B (zh) * 2010-04-30 2017-02-08 杭州九源基因工程有限公司 一种聚乙二醇修饰蛋白的分离纯化方法
RU2446173C1 (ru) * 2010-08-13 2012-03-27 Зао "Биокад" Новый функционально активный, высокоочищенный стабильный конъюгат гранулоцитарного колониестимулирующего фактора (г-ксф) с полиэтиленгликолем с пролонгированным биологическим действием, пригодный для медицинского применения, и иммунобиологическое средство на его основе
KR101831300B1 (ko) * 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
CN102485742A (zh) 2010-12-02 2012-06-06 山东新时代药业有限公司 一种聚乙二醇单修饰的重组人粒细胞集落刺激因子的制备及分离纯化方法
WO2012106463A2 (en) * 2011-02-01 2012-08-09 Fate Therapeutics, Inc. Cardiotrophin related molecules for enhanced therapeutics
US9422354B2 (en) * 2012-06-19 2016-08-23 Indian Institute Of Technology Delhi Process for purification of recombinant granulocyte colony stimulating factor (rHu GCSF)

Also Published As

Publication number Publication date
WO2016009451A2 (en) 2016-01-21
EP3169697A4 (en) 2017-11-08
EP3169697A2 (en) 2017-05-24
JP2017526649A (ja) 2017-09-14
US10519209B2 (en) 2019-12-31
AU2015291123B2 (en) 2020-03-12
EA035448B1 (ru) 2020-06-17
US20170210784A1 (en) 2017-07-27
AU2015291123C1 (en) 2020-12-10
PE20220371A1 (es) 2022-03-16
NZ728662A (en) 2021-01-29
PE20170769A1 (es) 2017-07-04
AU2015291123A1 (en) 2017-02-23
MX2017000467A (es) 2017-07-28
SA517380723B1 (ar) 2021-05-18
WO2016009451A3 (en) 2016-05-19
EA201700058A1 (ru) 2017-07-31
JP6742300B2 (ja) 2020-08-19
BR112017000704A2 (pt) 2017-11-14
CL2017000087A1 (es) 2018-05-18

Similar Documents

Publication Publication Date Title
ECSP17018120A (es) Triazolopirazinonas como inhibidores de pde1
ZA201606906B (en) Modified j-chain
CO2017001387A2 (es) Proceso para purificación de rhu-gcsf
DK3125836T3 (da) Vejrtrækningshjæpeapparat
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3142785T3 (da) Fremgangsmåde til fremstilling af alkenoler og anvendelse deraf til fremstilling af 1,3-butadien
BR112016022976A2 (pt) Métodos para o tratamento de hcv
DK3203834T3 (da) Hovbehandlingsarrangement
TWM476614U (en) Nose mask
DK3296485T3 (da) Ståldrager
PH12017500499A1 (en) Synthesis of ent-progesterone and intermediates thereof
GT201600213A (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1
ECSP16071574A (es) Hexahidrofuropirroles como inhibidores de pde1
HK1246271A1 (zh) 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途
DK3903774T3 (da) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of neurodegenerative diseases
CY1123685T1 (el) Μεθοδος πεγκυλιωσης
DK3393583T3 (da) Opløslig glycoprotein til behandling af trombotiske sygdomme
TH1601000862A (th) ระบบและวิธีการสำหรับการผลิตชิ้นส่วนเพื่อความปลอดภัยแบบแยกความเฉพาะ
DK3032283T3 (da) Tryktolerant seismisk kilde
TH1601000759A (th) การทรีทเม้นท์แก๊ส
TWD174553S (zh) 口罩
FI20146054A (fi) Tapahtumien aktiviteettien seuranta
FR3022871B1 (fr) Piece de recouvrement
TH1501006423A (th) การกลั่นส่วนของกระแส